Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Involvement of the JAK-STAT Pathway in the Molecular Landscape of Fusion-Free Myeloid Neoplasms with Eosinophilia

Blood (2023) 142 (Supplement 1): 78.

https://doi.org/10.1182/blood-2023-181250

Published: 2023

Journal Articles

Germline PAX5 mutation predisposes to familial B-cell precursor acute lymphoblastic leukemia

Blood (2021) 137 (10): 1424–1428.

https://doi.org/10.1182/blood.2020005756

Published: 2021

Includes: Supplemental data

Journal Articles

De Novo and Secondary Acute Myeloid Leukemia, Real World Data on Outcomes from the French Nord-Pas-De-Calais Picardie Acute Myeloid Leukemia Observatory

Loïc Renaud, Olivier Nibourel, PharmD, PhD, Celine Berthon, Christophe Roumier, Céline Rodriguez, Cecile Frimat, Catherine Roche-Lestienne, Aline Renneville, MD, Bruno Quesnel, MD PhD, Claude Preudhomme, MD PhD

Blood (2016) 128 (22): 4013.

https://doi.org/10.1182/blood.V128.22.4013.4013

Published: 2016

Journal Articles

AML At First Relapse: A Real Life Picture

Eileen Mary Boyle, MD, Claude Preudhomme, MD, PhD, Olivier Nibourel, Catherine Roche-Lestienne, PhD, Gareth J Morgan, MD PhD, Brigitte Dupriez, MD, Isabelle Plantier, MD, Berengere Gruson, MD, Jean Pierre Marolleau, MD, PhD, Delphine Lebon, MD, Jose Fernandes, MD, Christophe Willekens, Bruno Quesnel, MD, PhD, Céline Berthon, MD, PhD

Blood (2013) 122 (21): 3895.

https://doi.org/10.1182/blood.V122.21.3895.3895

Published: 2013

Journal Articles

MYD88 L265P mutation in Waldenstrom macroglobulinemia

Stéphanie Poulain, Christophe Roumier, Audrey Decambron, Aline Renneville, Charles Herbaux, Elisabeth Bertrand, Sabine Tricot, Agnès Daudignon, Sylvie Galiègue-Zouitina, Valerie Soenen, Olivier Theisen, Nathalie Grardel, Olivier Nibourel, Catherine Roche-Lestienne, Bruno Quesnel, Patrick Duthilleul, Claude Preudhomme, Xavier Leleu

Blood (2013) 121 (22): 4504–4511.

https://doi.org/10.1182/blood-2012-06-436329

Published: 2013

Journal Articles

Genome Wide SNP Array (SNPa) Analysis Reveals Clonal Evolution During Clinical Course in Waldenstrom's Macroglobulinemia (WM)

Stephanie Poulain, Christophe Roumier, Charles Herbaux, MD, Aline Renneville, MD, Elisabeth Bertrand, Agnes Daudignon, Sabine Tricot, MD, Valérie Soenen, Catherine Roche-Lestienne, Olivier Nibourel, Bruno Quesnel, MD, PhD, Claude Preudhomme, Patrick Duthilleul, Xavier Leleu, MD

Blood (2012) 120 (21): 297.

https://doi.org/10.1182/blood.V120.21.297.297

Published: 2012

Journal Articles

MYD88 L265P Mutation in Waldenstrom's Macroglogulinemia

Stephanie Poulain, Christophe Roumier, Audrey Decambron, Aline Renneville, MD, Charles Herbaux, MD, Elisabeth Bertrand, Sabine Tricot, MD, Agnes Daudignon, Sylvie Galiegue-Zouitina, Olivier Theisen, Nathalie Grardel, Valérie Soenen, Olivier Nibourel, Catherine Roche-Lestienne, Bruno Quesnel, Patrick Duthilleul, Claude Preudhomme, Xavier Leleu, MD, PhD

Blood (2012) 120 (21): 1307.

https://doi.org/10.1182/blood.V120.21.1307.1307

Published: 2012

Journal Articles

B-Cell-Specific Transcription Factor BACH2 Involved in the Clinical Behavior Heterogeneity of Waldenström Macroglobulinemia

Charles Herbaux, MD, Guillemette Marot, Elisabeth Bertrand, Natacha Broucqsault, Sylvie Zouitna-Galiègue, Christophe Roumier, Nicolas Poret, Valérie Soenen, Olivier Nibourel, Catherine Roche-Lestienne, Aline Renneville, Eileen Boyle, Guillemette Fouquet, MD, Sabine Tricot, MD, Claude Preudhomme, Bruno Quesnel, MD, PhD, Stephanie Poulain, Xavier Leleu, MD, PhD

Blood (2012) 120 (21): 1288.

https://doi.org/10.1182/blood.V120.21.1288.1288

Published: 2012

Journal Articles

Changes in the dynamics of the excess mortality rate in chronic phase-chronic myeloid leukemia over 1990-2007: a population study

Selim Corm, Laurent Roche, Jean-Baptiste Micol, Valérie Coiteux, Nadine Bossard, Franck-Emmanuel Nicolini, Jean Iwaz, Claude Preudhomme, Catherine Roche-Lestienne, Thierry Facon, Laurent Remontet

Blood (2011) 118 (16): 4331–4337.

https://doi.org/10.1182/blood-2011-01-330332

Published: 2011

Includes: Supplemental data

Journal Articles

Deletion of the Tumor Suppressor Gene NF1 Is Found In 3.5% of 485 De Novo Adult Myeloid Leukemia and Is Correlated with Unfavourable Cytogenetic: On Behalf of the ALFA Group

Blood (2010) 116 (21): 4171.

https://doi.org/10.1182/blood.V116.21.4171.4171

Published: 2010

Journal Articles

The Presence of the BCR-ABL T315I Mutation In Chronic Phase Chronic Myelogenous Leukemia Resistant to Tyrosine Kinase Inhibitors Profoundly Compromises Overall Survival and Progression Free Survival. Preliminary Results of a Matched Pair Analysis.

Blood (2010) 116 (21): 3410.

https://doi.org/10.1182/blood.V116.21.3410.3410

Published: 2010

Journal Articles

Mutations of TET2 , IDH1 , IDH2 and ASXL1 In Chronic Myeloid Leukemia.

Catherine Roche-Lestienne, Marceau Alice, Elise Labis, Olivier Nibourel, Valérie Coiteux, Joelle Guilhot, Laurence Legros, MD, Franck Nicolini, MD, PhD, Philippe Rousselot, MD, PhD, Martine Gardembas, Nathalie Helevaut, Cécile Frimat, Francois Guilhot, Claude Preudhomme

Blood (2010) 116 (21): 3377.

https://doi.org/10.1182/blood.V116.21.3377.3377

Published: 2010

Journal Articles

Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission

Blood (2010) 116 (7): 1132–1135.

https://doi.org/10.1182/blood-2009-07-234484

Published: 2010

Includes: Supplemental data

Journal Articles

Association of TET2 Alterations with NPM1 Mutations and Prognostic Value in De Novo Acute Myeloid Leukemia (AML).

Blood (2009) 114 (22): 163.

https://doi.org/10.1182/blood.V114.22.163.163

Published: 2009

Journal Articles

High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder

Claude Preudhomme, Aline Renneville, Violaine Bourdon, Nathalie Philippe, Catherine Roche-Lestienne, Nicolas Boissel, Nathalie Dhedin, Jean-Marie André, Pascale Cornillet-Lefebvre, André Baruchel, Marie-Joelle Mozziconacci, Hagay Sobol

Blood (2009) 113 (22): 5583–5587.

https://doi.org/10.1182/blood-2008-07-168260

Published: 2009

Includes: Supplemental data

Journal Articles

Randomized Comparison of Imatinib Versus Imatinib Combination Therapies in Newly Diagnosed Chronic Myeloid Leukaemia (CML) Patients in Chronic Phase (CP): First Results of the Phase III (SPIRIT) Trial from the French CML Group (FI LMC)

Blood (2008) 112 (11): 183.

https://doi.org/10.1182/blood.V112.11.183.183

Published: 2008

Journal Articles

RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL + leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance

Catherine Roche-Lestienne, Lauréline Deluche, Sélim Corm, Isabelle Tigaud, Sami Joha, Nathalie Philippe, Sandrine Geffroy, Jean-Luc Laï, Franck-Emmanuel Nicolini, Claude Preudhomme

Blood (2008) 111 (7): 3735–3741.

https://doi.org/10.1182/blood-2007-07-102533

Published: 2008

Includes: Supplemental data

Journal Articles

Evaluation of Minimal Residual Disease Based on NPM1 Mutations in AML with Intermediate Risk Cytogenetics: A Prospective Study of 36 Patients.

Aline Renneville, Florence Pasquier, Selim Corm, Nathalie Philippe, Charikleia Kelaidi, Catherine Roche-Lestienne, Virginie Eclache, Gerard Michel, Sylvie Castaigne, Pierre Fenaux, Claude Preudhomme

Blood (2007) 110 (11): 2847.

https://doi.org/10.1182/blood.V110.11.2847.2847

Published: 2007

Journal Articles

RUNX1 DNA-Binding Mutations and RUNX1-PRDM16 Cryptic Fusion in BCR/ABL+ Leukemias Are Frequently Associated with Secondary Trisomy 21 and May Contribute to Clonal Evolution and Imatinib Resistance.

Catherine Roche-Lestienne, PhD, Laureline Deluche, MD, Selim Corm, MD, Isabelle Tigaud, MD, Sami Joha, PhD, Nathalie Philippe, PhD, Sandrine Geffroy, PhD, Jean-Luc Lai, PhD, Franck Nicolini, MD, PhD, Claude Preudhomme, MD, PhD

Blood (2007) 110 (11): 2786.

https://doi.org/10.1182/blood.V110.11.2786.2786

Published: 2007

Journal Articles

Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA –positive chronic eosinophilic leukemia

Blood (2007) 109 (11): 4635–4640.

https://doi.org/10.1182/blood-2006-10-050054

Published: 2007

Includes: Supplemental data

NARROW

Involvement of the JAK-STAT Pathway in the Molecular Landscape of Fusion-Free Myeloid Neoplasms with Eosinophilia

Germline PAX5 mutation predisposes to familial B-cell precursor acute lymphoblastic leukemia

De Novo and Secondary Acute Myeloid Leukemia, Real World Data on Outcomes from the French Nord-Pas-De-Calais Picardie Acute Myeloid Leukemia Observatory

AML At First Relapse: A Real Life Picture

MYD88 L265P mutation in Waldenstrom macroglobulinemia

Genome Wide SNP Array (SNPa) Analysis Reveals Clonal Evolution During Clinical Course in Waldenstrom's Macroglobulinemia (WM)

MYD88 L265P Mutation in Waldenstrom's Macroglogulinemia

B-Cell-Specific Transcription Factor BACH2 Involved in the Clinical Behavior Heterogeneity of Waldenström Macroglobulinemia

Changes in the dynamics of the excess mortality rate in chronic phase-chronic myeloid leukemia over 1990-2007: a population study

Deletion of the Tumor Suppressor Gene NF1 Is Found In 3.5% of 485 De Novo Adult Myeloid Leukemia and Is Correlated with Unfavourable Cytogenetic: On Behalf of the ALFA Group

The Presence of the BCR-ABL T315I Mutation In Chronic Phase Chronic Myelogenous Leukemia Resistant to Tyrosine Kinase Inhibitors Profoundly Compromises Overall Survival and Progression Free Survival. Preliminary Results of a Matched Pair Analysis.

Mutations of TET2 , IDH1 , IDH2 and ASXL1 In Chronic Myeloid Leukemia.

Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission

Association of TET2 Alterations with NPM1 Mutations and Prognostic Value in De Novo Acute Myeloid Leukemia (AML).

High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder

Randomized Comparison of Imatinib Versus Imatinib Combination Therapies in Newly Diagnosed Chronic Myeloid Leukaemia (CML) Patients in Chronic Phase (CP): First Results of the Phase III (SPIRIT) Trial from the French CML Group (FI LMC)

RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL + leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance

Evaluation of Minimal Residual Disease Based on NPM1 Mutations in AML with Intermediate Risk Cytogenetics: A Prospective Study of 36 Patients.

RUNX1 DNA-Binding Mutations and RUNX1-PRDM16 Cryptic Fusion in BCR/ABL+ Leukemias Are Frequently Associated with Secondary Trisomy 21 and May Contribute to Clonal Evolution and Imatinib Resistance.

Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA –positive chronic eosinophilic leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only